2026 Global: Cardiac Valve Market-Competitive Review (2032) report
Description
The 2026 Global: Cardiac Valve Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiac valve market by geography and historical trend. The scope of the report extends to sizing of the cardiac valve market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Edwards Lifesciences, Medtronic, Abbott, Boston Scientific, LivaNova, MicroPort, Meril Life Sciences, Lepu Medical, JenaValve, and Corcym are among the ten major companies shaping the global cardiac valve market through competing portfolios of surgical and transcatheter solutions. Edwards Lifesciences leads with its SAPIEN family for TAVR and a broad surgical valve line that underpins a dominant share of the U.S. TAVR market, supported by acquisitions to broaden access to aortic regurgitation and mitral/tricuspid therapies. Medtronic’s CoreValve/Evolut series and Harmony pulmonary valve provide a wide offering across aortic, pulmonary, and other structural indications, reflecting the company’s strength in self‑expanding nitinol platforms and global reach. Abbott competes strongly in transcatheter mitral and tricuspid spaces with devices like Tendyne and Navitor (and MitraClip in repair), positioning itself to challenge the aortic duopoly through active pivotal programs and imaging integration efforts. Boston Scientific’s structural heart activities historically focused on transcatheter replacement and repair approaches, though its Acurate TAVR program faced setbacks and strategic realignments in 2025, while the company continues to invest in minimally invasive valve technologies and global regulatory engagement.
LivaNova and MicroPort represent important specialized and regional players that expand choice and price points across surgical and transcatheter segments. LivaNova’s heritage in mechanical and tissue surgical valves and emphasis on miniaturization supports complex and pediatric applications, while MicroPort’s VitaFlow family and regional commercialization strengths have increased access across Asia‑Pacific and emerging markets. Meril Life Sciences’ MyVal system has secured CE marking and regional adoption as a cost‑competitive TAVR alternative from India, enabling broader patient access and fostering competition on price and localized support. Lepu Medical of China has grown through domestic R&D and distribution networks to serve both tissue and mechanical valve needs regionally and in export markets, contributing to more diversified global supply chains. JenaValve, with designs aimed at challenging current aortic and mitral approaches (including AR indications), remains notable for innovation targeted at complex anatomies and is central to recent industry consolidation and trial activity. Corcym (formerly part of Sorin/Churchill) supplies sutureless surgical valves, annuloplasty rings, and repair devices, reinforcing the surgical repair/replacement segment and offering alternatives for selected operative strategies.
Collectively these ten firms drive technological progress, competitive pricing, and geographic expansion that define the cardiac valve market’s trajectory toward broader minimally invasive adoption and indication expansion. Market leadership is concentrated—Edwards and Medtronic retain the largest TAVR shares—yet newcomers and regional champions (Anteris, Foldax, Meril, MicroPort, Lepu) and specialized surgical innovators (LivaNova, Corcym) push diversification via novel materials, polymer and tissue engineering, and platform differentiation reported across industry analyses and market studies. Regulatory milestones, pivotal trial results, and strategic M&A continue to reshape competitive positions, while affordability and local manufacturing remain key drivers for expansion in Asia‑Pacific and emerging markets according to recent market reports and industry commentary.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiac valve market by geography and historical trend. The scope of the report extends to sizing of the cardiac valve market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Edwards Lifesciences, Medtronic, Abbott, Boston Scientific, LivaNova, MicroPort, Meril Life Sciences, Lepu Medical, JenaValve, and Corcym are among the ten major companies shaping the global cardiac valve market through competing portfolios of surgical and transcatheter solutions. Edwards Lifesciences leads with its SAPIEN family for TAVR and a broad surgical valve line that underpins a dominant share of the U.S. TAVR market, supported by acquisitions to broaden access to aortic regurgitation and mitral/tricuspid therapies. Medtronic’s CoreValve/Evolut series and Harmony pulmonary valve provide a wide offering across aortic, pulmonary, and other structural indications, reflecting the company’s strength in self‑expanding nitinol platforms and global reach. Abbott competes strongly in transcatheter mitral and tricuspid spaces with devices like Tendyne and Navitor (and MitraClip in repair), positioning itself to challenge the aortic duopoly through active pivotal programs and imaging integration efforts. Boston Scientific’s structural heart activities historically focused on transcatheter replacement and repair approaches, though its Acurate TAVR program faced setbacks and strategic realignments in 2025, while the company continues to invest in minimally invasive valve technologies and global regulatory engagement.
LivaNova and MicroPort represent important specialized and regional players that expand choice and price points across surgical and transcatheter segments. LivaNova’s heritage in mechanical and tissue surgical valves and emphasis on miniaturization supports complex and pediatric applications, while MicroPort’s VitaFlow family and regional commercialization strengths have increased access across Asia‑Pacific and emerging markets. Meril Life Sciences’ MyVal system has secured CE marking and regional adoption as a cost‑competitive TAVR alternative from India, enabling broader patient access and fostering competition on price and localized support. Lepu Medical of China has grown through domestic R&D and distribution networks to serve both tissue and mechanical valve needs regionally and in export markets, contributing to more diversified global supply chains. JenaValve, with designs aimed at challenging current aortic and mitral approaches (including AR indications), remains notable for innovation targeted at complex anatomies and is central to recent industry consolidation and trial activity. Corcym (formerly part of Sorin/Churchill) supplies sutureless surgical valves, annuloplasty rings, and repair devices, reinforcing the surgical repair/replacement segment and offering alternatives for selected operative strategies.
Collectively these ten firms drive technological progress, competitive pricing, and geographic expansion that define the cardiac valve market’s trajectory toward broader minimally invasive adoption and indication expansion. Market leadership is concentrated—Edwards and Medtronic retain the largest TAVR shares—yet newcomers and regional champions (Anteris, Foldax, Meril, MicroPort, Lepu) and specialized surgical innovators (LivaNova, Corcym) push diversification via novel materials, polymer and tissue engineering, and platform differentiation reported across industry analyses and market studies. Regulatory milestones, pivotal trial results, and strategic M&A continue to reshape competitive positions, while affordability and local manufacturing remain key drivers for expansion in Asia‑Pacific and emerging markets according to recent market reports and industry commentary.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
